tiprankstipranks
Trending News
More News >
OnKure Therapeutics (OKUR)
NASDAQ:OKUR
US Market

OnKure Therapeutics (OKUR) Ratios

Compare
409 Followers

OnKure Therapeutics Ratios

OKUR's free cash flow for Q3 2025 was $0.00. For the 2025 fiscal year, OKUR's free cash flow was decreased by $ and operating cash flow was $0.00. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
11.45 4.64 2.46--
Quick Ratio
11.45 4.64 2.46--
Cash Ratio
11.26 4.10 2.08--
Solvency Ratio
-10.22 -0.25 -0.41--
Operating Cash Flow Ratio
-9.82 -4.74 -4.86--
Short-Term Operating Cash Flow Coverage
-108.17 0.00 0.00--
Net Current Asset Value
$ 65.12M$ -103.81M$ -56.79M--
Leverage Ratios
Debt-to-Assets Ratio
<0.01 0.02 0.04--
Debt-to-Equity Ratio
0.01 >-0.01 -0.01--
Debt-to-Capital Ratio
0.01 >-0.01 -0.01--
Long-Term Debt-to-Capital Ratio
<0.01 0.00 0.00--
Financial Leverage Ratio
1.10 -0.35 -0.29--
Debt Service Coverage Ratio
-139.16 0.00 0.00--
Interest Coverage Ratio
41.31K 0.00 0.00--
Debt to Market Cap
0.02 0.00 0.00--
Interest Debt Per Share
<0.01 0.05 0.05--
Net Debt to EBITDA
0.89 0.84 0.37--
Profitability Margins
Gross Profit Margin
0.00%0.00%0.00%--
EBIT Margin
0.00%0.00%0.00%--
EBITDA Margin
0.00%0.00%0.00%--
Operating Profit Margin
0.00%0.00%0.00%--
Pretax Profit Margin
0.00%0.00%0.00%--
Net Profit Margin
0.00%0.00%0.00%--
Continuous Operations Profit Margin
0.00%0.00%0.00%--
Net Income Per EBT
100.00%100.00%100.00%--
EBT Per EBIT
80.50%95.61%99.15%--
Return on Assets (ROA)
-91.31%-98.82%-184.46%--
Return on Equity (ROE)
-78.46%34.67%54.23%--
Return on Capital Employed (ROCE)
-124.08%-129.83%-284.65%--
Return on Invested Capital (ROIC)
-123.03%-128.88%-280.60%--
Return on Tangible Assets
-91.31%-98.82%-184.46%--
Earnings Yield
-15.80%-15.95%-9.50%--
Efficiency Ratios
Receivables Turnover
0.00 0.00 0.00--
Payables Turnover
0.65 0.00 0.00--
Inventory Turnover
0.00 0.00 0.00--
Fixed Asset Turnover
0.00 0.00 0.00--
Asset Turnover
0.00 0.00 0.00--
Working Capital Turnover Ratio
0.00 0.00 0.00--
Cash Conversion Cycle
-558.54 0.00 0.00--
Days of Sales Outstanding
0.00 0.00 0.00--
Days of Inventory Outstanding
0.00 0.00 0.00--
Days of Payables Outstanding
558.54 0.00 0.00--
Operating Cycle
0.00 0.00 0.00--
Cash Flow Ratios
Operating Cash Flow Per Share
-0.45 -2.59 -2.02--
Free Cash Flow Per Share
-0.45 -2.61 -2.11--
CapEx Per Share
<0.01 0.02 0.09--
Free Cash Flow to Operating Cash Flow
1.00 1.01 1.04--
Dividend Paid and CapEx Coverage Ratio
-704.95 -140.43 -23.77--
Capital Expenditure Coverage Ratio
-704.95 -140.43 -23.77--
Operating Cash Flow Coverage Ratio
-89.27 -51.26 -42.31--
Operating Cash Flow to Sales Ratio
0.00 0.00 0.00--
Free Cash Flow Yield
-145.77%-15.71%-9.04%--
Valuation Ratios
Price-to-Earnings (P/E) Ratio
-6.33 -6.27 -10.53--
Price-to-Sales (P/S) Ratio
0.00 0.00 0.00--
Price-to-Book (P/B) Ratio
6.33 -2.17 -5.71--
Price-to-Free Cash Flow (P/FCF) Ratio
-0.69 -6.36 -11.07--
Price-to-Operating Cash Flow Ratio
-6.86 -6.41 -11.53--
Price-to-Earnings Growth (PEG) Ratio
0.41 -0.31 0.00--
Price-to-Fair Value
6.33 -2.17 -5.71--
Enterprise Value Multiple
0.35 -5.53 -10.21--
Enterprise Value
-27.51M 192.23M 299.90M--
EV to EBITDA
0.35 -5.53 -10.21--
EV to Sales
0.00 0.00 0.00--
EV to Free Cash Flow
0.45 -5.53 -10.68--
EV to Operating Cash Flow
0.45 -5.56 -11.13--
Tangible Book Value Per Share
0.49 -7.63 -4.08--
Shareholders’ Equity Per Share
0.49 -7.63 -4.08--
Tax and Other Ratios
Effective Tax Rate
0.00 0.00 0.00--
Revenue Per Share
0.00 0.00 0.00--
Net Income Per Share
-0.49 -2.65 -2.21--
Tax Burden
1.00 1.00 1.00--
Interest Burden
1.04 1.00 0.99--
Research & Development to Revenue
0.00 0.00 0.00--
SG&A to Revenue
0.00 0.00 0.00--
Stock-Based Compensation to Revenue
0.00 0.00 0.00--
Income Quality
0.76 0.98 0.91--
Currency in USD